Cutia Therapeutics successfully listed on the Hong Kong Stock Exchange
2023-06-12
On June 12, 2023, Cutia Therapeutics was officially listed on the Main Board of the Hong Kong Stock Exchange with the stock code of 02487.HK.
Cutia Therapeutics is an R&D biopharmaceutical company focused on dermatology, developing innovative and comprehensive solutions to meet the changing needs of patients and consumers in the broad dermatological treatment and care market. At present, the company has successfully marketed two products and is developing five clinical stage and four preclinical stage drug candidates, of which two clinical stage products have begun commercial pilots.
The intermediary team of this listing is:
Goldman Sachs and CICC are co-sponsors;
Davis Polk & Wardwell served as the company's legal counsel in Hong Kong and the United States, and Zhong Lun Law Firm served as the company's legal counsel in China.
Herbert Smith Freehills is the underwriters' Hong Kong and US legal counsel, while CM Law Firm is the underwriters' China legal counsel;
Ernst & Young provides audit services;
Frost & Sullivan is an industry consultant.
